AVITA Medical to Host Investor Webinar Briefing
February 14 2025 - 8:15AM
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic
acute wound care company delivering transformative solutions,
invites shareholders and prospective investors to attend its
investor webinar briefing and presentation by Jim Corbett, Chief
Executive Officer, and David O’Toole, Chief Financial Officer, on
February 18, 2025, at 2:00 p.m. Pacific Standard Time (February 19,
2025, at 9:00 a.m. Australian Eastern Daylight Time).
The webinar presentation will cover financial and business
results from our recent fourth quarter and full-year 2024 earnings
webcast and will conclude with a Q&A session. Participants are
invited to submit their questions via the registration page.
To register for the presentation, please follow this Zoom link:
https://us02web.zoom.us/webinar/register/WN_Nx3kCIIOSmOj686nctwpRA.A
replay will be available on the AVITA Medical website,
ir.avitamedical.com, following the presentation.
About AVITA Medical, Inc.AVITA Medical® is a
leading therapeutic acute wound care company delivering
transformative solutions. Our technologies optimize wound healing,
effectively accelerating the time to patient recovery. At the
forefront of our platform is the RECELL® System, approved by the
U.S. Food and Drug Administration for the treatment of thermal burn
wounds and full-thickness skin defects. RECELL harnesses the
healing properties of a patient’s own skin to create Spray-On Skin™
Cells, offering a groundbreaking solution for improved clinical
outcomes at the point-of-care. In the U.S., AVITA Medical also
holds the exclusive rights to market, sell, and distribute
Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix,
and PermeaDerm®, a biosynthetic wound matrix.
In international markets, the RECELL System is approved to
promote skin healing in a wide range of applications including
burns and full-thickness skin defects. The RECELL System, excluding
RECELL GO®, is TGA-registered in Australia, has received CE mark
approval in Europe, and has PMDA approval in Japan.
To learn more, visit www.avitamedical.com.
Authorized for release by the Chief Financial Officer of AVITA
Medical, Inc.
Investor & Media Contact:
Jessica Ekeberg
Phone +1-661-904-9269
investor@avitamedical.com
media@avitamedical.com
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Jan 2025 to Feb 2025
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Feb 2024 to Feb 2025